Moving Towards a New Copyright Bargain – Lecture by Rebecca Giblin
[PIJIP Events: September 3, 2019 | 6:00pm EST] Copyright laws are beset from every angle. They’re criticized for failing to recognize and reward creators, for blocking new forms of creativity, for limiting access to knowledge and for causing culture to be lost. Copyright’s fundamental structures were settled before the digital era, but are cemented in by outdated and effectively unamendable treaties. In this public lecture, Associate Professor and ARC Future Fellow Rebecca Giblin will illuminate a path forward to a new copyright bargain: one that, by taking authors’ interests seriously, would simultaneously reclaim lost culture, promote access to knowledge and help authors get paid – all within those unamendable treaty frameworks. Click here for more info, or to view the webcast.
Shamnad Basheer IP/Trade Fellowship with Texas A&M University School of Law
[Srividhya Ragavan] In memory of Shamnad Basheer the founder of SpicyIP and IDIA, the Association for Accessible Medicines in collaboration with the Texas A&M University School of Law invites applications for the Shamnad Basheer IP/Trade Fellowship with Texas A&M University School of Law. The fellow will work closely with Professor Srividhya Ragavan of Texas A&M University School of Law and Jonathan Kimball of the Association for Accessible Medicines to produce a white paper that examines the Special 301 submissions of the Pharmaceutical Research and Manufacturers of America to the Office of the U.S. Trade Representative (USTR). The fellow will evaluate the submissions’ role and impact on USTR policymaking and their consistency with the approach to intellectual property protection and enforcement outlined in the Bipartisan Congressional Trade Priorities and Accountability Act of 2015 (Trade Promotion Authority) and the May 10 Agreement concerning international trade negotiations and access to healthcare and pharmaceutical innovation.Click here for more.
When Markets Fail: Patents and Infectious Disease Products
[Jonathan J. Darrow, Michael S. Sinha and Aaron S. Kesselheim] Abstract: New antibiotics and vaccines aimed at treating or preventing infectious diseases can be highly valuable public health innovations, particularly when these products address unmet medical needs. Although patents are considered the primary means of incentivizing new product development, reduced private investment in this area has led policymakers to create new and sometimes costly supplemental incentive schemes for antibiotics. But the legislative initiatives launched over the past 15 years to overcome the shortcomings of the patent system have had limited success, in part because they do not adequately address the reasons underlying the disconnect between patents and the antimicrobial market. Click here for more.
Finally! The Text of Poland’s Legal Challenge of Copyright Directive Was Published
[Natalia Mileszyk] Earlier this year, Poland initiated a legal challenge against Article 17 of the Directive on copyright in the Digital Single Market before the Court of Justice of the European Union (CJEU) [C-401/19]. The CJEU has finally published the application for this legal challenge… In our opinion, referring the Directive to the Court of Justice is a good step that can help clear controversies concerning Article 17. An independent court will assess issues that in the policy debate are usually dismissed by representatives of rightsholders as fear-mongering or disinformation. Click here for more.
